NCT00611351 · OUTCOME

Overall Survival

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Analysis population: Count of participants is the number of participant alive at the 2 year post transplant time point.

Groups in this outcome

Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Unrelated Donor Allogeneic	5

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Unrelated Donor Allogeneic	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

Count of participants is the number of participant alive at the 2 year post transplant time point.

reporting Status

POSTED

time Frame

2 years post transplant

title

Overall Survival

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice